Night vision test could spot early eye disease

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Participants will be eligible if the following inclusion criteria are met: * Participant is able to understand and sign the protocol s informed consent document. * Participant is able to complete and comply with study assessments for the full duration of the study. * Participant is \>= 50 years of age. * Participant has a BCVA score of \>= 20/100 (Snellen equivalent) in study eye. * Participant qualifies for one of the following groups based on AMD grading as defined below. * Group 0: Participant without AMD defined as no large drusen or advanced AMD in either eye; * Group 1: Participant has at least one large drusen (\>= 125 microns) in the study eye and no large drusen or advanced AMD in the fellow eye; * Group 2: Participant has bilateral large drusen (\>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes; * Group 3: Participant has at least one large drusen (\>= 125 microns) in the study eye and advanced AMD in the fellow eye. * Group 4: Participant has reticular pseudodrusen in the study eye defined as having (1) the presence of RPD on at least one en face imaging method (color photography, autofluorescence or infrared) and (2) confirmation of previously described findings of hyperreflective material located between the RPE and the photoreceptor ellipsoid zone on SD OCT in those areas. EXCLUSION CRITERIA: Participants who meet any of the following criteria will be excluded from this study: * Participant has advanced AMD in the study eye at the baseline visit. * Participant has other active ocular or macular diseases (e.g., diabetic macular edema, retinal vein occlusion, Stargardt's disease or cone-rod dystrophy) or other known ocular disorders that have caused a visual field deficit (e.g., glaucoma with known visual field defect) in the study eye. * Participant has a fixation deficit in the study eye that would prevent the participant from performing the AdaptDxTM dark adaptation protocol. * Participant has a medical condition that the investigator feels would prevent the participant from complying with or being able to complete the study assessments. * Participant had cataract surgery in the study eye within three months prior to enrollment. * Participant has an oral intake of high doses of vitamin A palmitate supplement (\>= 10,000 international units (IU) per day). * Participant has or had hepatitis or liver disease. Abnormally low vitamin A can alter dark adaptation and chronic liver disease has been associated with low vitamin A. * Participant has a history of vitamin A deficiency. * Participant is an NEI employee or subordinate or co-worker of an investigator.